PMC:7195088 / 63642-63938 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1883","span":{"begin":50,"end":83},"obj":"Gene"},{"id":"1884","span":{"begin":187,"end":195},"obj":"Species"},{"id":"1885","span":{"begin":167,"end":186},"obj":"Disease"}],"attributes":[{"id":"A1883","pred":"tao:has_database_id","subj":"1883","obj":"Gene:3557"},{"id":"A1884","pred":"tao:has_database_id","subj":"1884","obj":"Tax:9606"},{"id":"A1885","pred":"tao:has_database_id","subj":"1885","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Other immune-modulatory drugs including anakinra (interleukin 1 receptor antagonist) or Janus kinase family enzyme inhibitors have been proposed for the management of SARS-CoV-2–infected patients. Notably, there is currently no supporting clinical evidence, and RCT are ongoing (Table 2) [67,73]."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T110","span":{"begin":50,"end":63},"obj":"Body_part"},{"id":"T111","span":{"begin":50,"end":61},"obj":"Body_part"}],"attributes":[{"id":"A110","pred":"fma_id","subj":"T110","obj":"http://purl.org/sig/ont/fma/fma86583"},{"id":"A111","pred":"fma_id","subj":"T111","obj":"http://purl.org/sig/ont/fma/fma86578"}],"text":"Other immune-modulatory drugs including anakinra (interleukin 1 receptor antagonist) or Janus kinase family enzyme inhibitors have been proposed for the management of SARS-CoV-2–infected patients. Notably, there is currently no supporting clinical evidence, and RCT are ongoing (Table 2) [67,73]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T370","span":{"begin":167,"end":175},"obj":"Disease"}],"attributes":[{"id":"A370","pred":"mondo_id","subj":"T370","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Other immune-modulatory drugs including anakinra (interleukin 1 receptor antagonist) or Janus kinase family enzyme inhibitors have been proposed for the management of SARS-CoV-2–infected patients. Notably, there is currently no supporting clinical evidence, and RCT are ongoing (Table 2) [67,73]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T355","span":{"begin":50,"end":63},"obj":"http://purl.obolibrary.org/obo/PR_000001091"}],"text":"Other immune-modulatory drugs including anakinra (interleukin 1 receptor antagonist) or Janus kinase family enzyme inhibitors have been proposed for the management of SARS-CoV-2–infected patients. Notably, there is currently no supporting clinical evidence, and RCT are ongoing (Table 2) [67,73]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T42677","span":{"begin":24,"end":29},"obj":"Chemical"},{"id":"T26418","span":{"begin":73,"end":83},"obj":"Chemical"},{"id":"T58620","span":{"begin":108,"end":125},"obj":"Chemical"},{"id":"T9262","span":{"begin":115,"end":125},"obj":"Chemical"}],"attributes":[{"id":"A51674","pred":"chebi_id","subj":"T42677","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A77192","pred":"chebi_id","subj":"T26418","obj":"http://purl.obolibrary.org/obo/CHEBI_48706"},{"id":"A53928","pred":"chebi_id","subj":"T58620","obj":"http://purl.obolibrary.org/obo/CHEBI_23924"},{"id":"A48058","pred":"chebi_id","subj":"T9262","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"Other immune-modulatory drugs including anakinra (interleukin 1 receptor antagonist) or Janus kinase family enzyme inhibitors have been proposed for the management of SARS-CoV-2–infected patients. Notably, there is currently no supporting clinical evidence, and RCT are ongoing (Table 2) [67,73]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T457","span":{"begin":0,"end":196},"obj":"Sentence"},{"id":"T458","span":{"begin":197,"end":296},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Other immune-modulatory drugs including anakinra (interleukin 1 receptor antagonist) or Janus kinase family enzyme inhibitors have been proposed for the management of SARS-CoV-2–infected patients. Notably, there is currently no supporting clinical evidence, and RCT are ongoing (Table 2) [67,73]."}

{"project":"2_test","denotations":[{"id":"32360444-32192578-22369814","span":{"begin":289,"end":291},"obj":"32192578"},{"id":"32360444-32032529-22369815","span":{"begin":292,"end":294},"obj":"32032529"}],"text":"Other immune-modulatory drugs including anakinra (interleukin 1 receptor antagonist) or Janus kinase family enzyme inhibitors have been proposed for the management of SARS-CoV-2–infected patients. Notably, there is currently no supporting clinical evidence, and RCT are ongoing (Table 2) [67,73]."}